Piper Sandler Maintains Neutral on NovoCure, Raises Price Target to $80
Piper Sandler analyst Jason Bednar maintains NovoCure (NASDAQ:NVCR) with a Neutral and raises the price target from $70 to $80.
JP Morgan Maintains Neutral on NovoCure, Raises Price Target to $99
JP Morgan analyst Jessica Fye maintains NovoCure (NASDAQ:NVCR) with a Neutral and raises the price target from $86 to $99.
Benzinga’s Top Ratings Upgrades, Downgrades For January 6, 2023
Upgrades Piper Sandler upgraded the previous rating for Aligos Therapeutics Inc (NASDAQ:ALGS) from Neutral to Overweight. Aligos Therapeutics…
Tesla, Amazon, Aehr, Silvergate, Novocure: Why These 5 Stocks Are Drawing Investors’ Attention Today
Major Wall Street indices closed over 1% lower on Thursday, dragged by strong employment data which could nudge the Federal Reserve to continue its rate hikes.
Dow Falls Over 200 Points; Walgreens Earnings Top Expectations
U.S. stocks traded lower toward the end of trading, with the Dow Jones dropping over 200 points on Thursday.
Nasdaq Down Over 100 Points; Crude Oil Rises 1%
U.S. stocks traded lower midway through trading, with the Nasdaq Composite shedding more than 100 points on Thursday.
Novocure Stock Surges As Tumor Treating Fields Shows Overall Survival In Lung Cancer Patients
Zai Lab Limited (NASDAQ:ZLAB) and Novocure Ltd (NASDAQ:NVCR) announced that the LUNAR study met its primary endpoint, demonstrating a statistically significant and…
Novocure Announces Pivotal LUNAR Study In Non-Small Cell Lung Cancer Met Primary Overall Survival Endpoint
The LUNAR study met its primary endpoint, demonstrating a statistically significant and clinically meaningful improvement in overall survival
The full LUNAR data will be presented at a future medical congress
Novocure
10 Health Care Stocks Whale Activity In Today’s Session
This whale alert can help traders discover the next big trading opportunities.
Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner.
Where NovoCure Stands With Analysts
Analysts have provided the following ratings for NovoCure (NASDAQ:NVCR) within the last quarter: Bullish Somewhat Bullish Indifferent Somewhat…